BPA for keveyis
Ended Awarded Last action
- Contract number
- 36E79722A0022
- Awardee
-
Xeris Pharmaceuticals, Inc. UEI YAV5AK7VKJ31
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $661,240.80
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Xeris Pharmaceuticals, Inc. for the provision of KEVEYIS, a pharmaceutical product used to treat hyperkalemic periodic paralysis. The BPA, valued at $661,240.80, was awarded on June 17, 2022, with an ultimate completion date of March 31, 2026. This procurement falls under the parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and does not utilize a small business set-aside. As the prime contractor, Xeris Pharmaceuticals, a small disadvantaged business registered in the System for Award Management (SAM.gov), delivers this critical therapeutic medication to support the VA's healthcare operations for veteran patients requiring treatment for hyperkalemic periodic paralysis.
The BPA streamlines the ordering process for KEVEYIS by establishing predetermined contract terms and pricing under the VA's Integrated Service Network 12 framework, enabling efficient procurement and consistent supply of this specialty pharmaceutical to the federal government. This agreement represents a focused acquisition vehicle for a specific, clinically necessary drug therapy and demonstrates the VA's utilization of multiple contract mechanisms—including Federal Supply Schedule contracts and targeted BPAs—to ensure reliable access to essential medications for the veteran population. The award to Xeris leverages the company's existing Federal Supply Schedule contracts with the VA to facilitate expedited procurement of KEVEYIS in support of ongoing healthcare delivery missions.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Show all 11
Quick answers
Who was awarded contract 36E79722A0022?
36E79722A0022 was awarded to Xeris Pharmaceuticals, Inc. by National Acquisition Center (Headquarters) on June 17, 2022.
How much is contract 36E79722A0022 worth?
36E79722A0022's own ceiling is $661,241.
Who can order from contract 36E79722A0022?
36E79722A0022 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79722A0022 under another contract?
Yes. 36E79722A0022 is a blanket purchase agreement under 36F79720D0153, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79722A0022 competed?
The extent of competition for 36E79722A0022 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV